期刊文献+

二甲双胍调控IL-6/STAT3信号通路对大鼠肝癌血管形成的影响 被引量:3

The effect of metformin-regulated IL-6/STAT3 signaling pathway on the angiogenesis of liver cancer in rats
在线阅读 下载PDF
导出
摘要 目的初步探究二甲双胍(MET)对大鼠肝癌血管形成影响及其作用机制。方法60只Wistar大鼠,按照随机数字表法分为对照组、模型组MET低剂量组(10 mgkg)、MET中剂量组(20 mg/kg)、MET高剂量组(40 mg/kg)、阳性对照药组,每组10只,腹腔注射二乙基亚硝铵(DEN)诱导大鼠肝癌模型,苏木素-伊红(HE)染色观察各组大鼠肝脏组织形态学变化;酶联吸附法(ELISA)测定各组大鼠血清中VEGF含量以及肝功能指标(ALT、AST、ALP和TBIL等);免疫组化检测肝组织VEGF阳性表达情况;蛋白质免疫印迹法(Westerm bloting)检测各组大鼠肝组织IL-6、p-STAT3蛋白表达。结果与对照组相比,模型组大鼠肝组织多处坏死,伴有明显的形态异常,血清VEGF、ALT、AST、ALP和TBIL含量均显著性升高(均P<0.01),肝组织IL-6、p-STAT3蛋白表达均显著性升高(均P<0.01),VEGF蛋白阳性表达率升高(均P<0.01)。与模型组相比,MET不同剂量处理组肝组织坏死减轻,细胞变性程度减轻,VEGF、ALT、AST、ALP和TBIL,均含量降低(P<0.05或P<0.01),IL6、p-STAT3蛋白表达显著性降低(P<0.05或P<0.01),VEGF蛋白阳性表达率降低(P<0.01)。结论MET能够抑制大鼠肝癌血管生成,其机制可能与抑制IL-6/STAT3信号通路降低VEGF表达相关。 Objective To preliminarily explore the effect of metformin(MET)on the angiogenesis of liver cancer in rats and its mechanism.Methods 60 Wistar rats were divided into control group,model group,MET low-dose group(10 mg/kg),MET medium-dose group(20 mg/kg),and MET high-dose group(40 mg/kg)according to the random number table method,kg),positive control group,10 rats in each group,intraperitoneal injection of diethyl nitrite(DEN)to induce rat liver cancer model,hematoxylin-eosin(HE)staining to observe the morphological changes of rat liver tissue in each group;enzymes ELISA was used to determine the serum VEGF content and liver function indexes(ALT,AST,ALP,TBIL,etc.)of rats in each group;immunohistochemistry to detect the positive expression of VEGF in liver tissue;The expression of IL-6 and p-STAT3 protein in liver tissue of rats in each group by Western blotting;.Results Compared with the control group,the rats in the model group had multiple necrosis in liver tissues,accompanied by obvious morphological abnormalities.The serum VEGF,ALT,AST,ALP and TBIL levels were significantly increased(all P<0.01),and the liver tissue IL-6.The expression of p-STAT3 protein increased significantly(all P<0.01),and the positive expression rate of VEGF protein increased(all P<0.01).Compared with the model group,the different doses of MET treatment group reduced liver tissue necrosis,reduced cell degeneration,decreased VEGF,ALT,AST,ALP and TBIL levels(P<0.05 or P<0.01),IL-6,p-STAT3 The protein expression decreased significantly(P<0.05 or P<0.01),and the positive expression rate of VEGF protein decreased(P<0.01).Conclusion MET can inhibit the angiogenesis of liver cancer in rats,and its mechanism may be related to inhibiting IL-6/STAT3 signaling pathway and reducing the expression of VEGF.
作者 陈冠吉 王春燕 CHEN Guan-ji;WANG Chun-yan(Zhangjiagang Hospital of Traditional Chinese Medicine,Zhangjiagang 215600,China)
出处 《肝胆外科杂志》 2022年第2期149-153,共5页 Journal of Hepatobiliary Surgery
关键词 二甲双胍 肝癌 血管形成 IL-6/STAT3信号通路 liver cancer metformin angiogenesis IL-6/STAT3 signaling pathway
  • 相关文献

参考文献9

二级参考文献108

  • 1朱海英,张朵,谢东甫,王新民,周旭宇,Joseph T Lau,胡以平.人肝癌细胞系P2-HCC的建立及体外诱导分化特性的初步研究[J].第二军医大学学报,2005,26(3):247-250. 被引量:16
  • 2丁雄,王梦远,刘作金,李生伟,龚建平.Kupffer细胞在原发性肝细胞癌患者肝脏中的分布及意义[J].第三军医大学学报,2007,29(11):1076-1078. 被引量:3
  • 3Jenab-Wolcott J, Giantonio BJ. Bevacizumab: Current indications and future development for management of solid tumors [J]. Expert Opin Biol Ther, 2009, 9 (4):507.
  • 4Jain R K, et al. Lessons from phase Ⅲ clinical trials on anti-VEGF therapy for cancer [J]. Nat Clin Pratt Oncol, 2006, 3 : 24.
  • 5Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer [ J ]. Pharmacotherapy, 2008, 28 ( 11 Pt 2) : S23.
  • 6Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase Ⅱ study [J]. J Clin Oncol, 2009, 27(18) :3020.
  • 7Willett CG, Kozin SV, Duda DG. et al. Combined VEGF- targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice [J]. Semin Oncol, 2006, 33 (5 Suppl 10): s35.
  • 8Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer [J]. Semin Oncol, 2006, 33:S1.
  • 9Sandier A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [ J ]. N Engl J Med, 2006, 355 : 2542.
  • 10Motzer RJ, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma [J]. N Engl J Med, 2007, 356: 115.

共引文献92

同被引文献21

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部